The clinical efficacy of the “one-two-punch” hypothesis is currently evaluated with vorinostat treatment in patients with resistant BRAF V600E mutated advanced melanoma [207], and the results will hopefully prove that the concept is clinically relevant. This evidence concerns the gene BRAF and melanoma.